Fig. 5.

Clinical and immune responses to personalized Neo-DCVac in patient 17. a Clinical course of the disease and previous treatments of patient 17. The patient failed three lines of chemotherapy, radiotherapy and PD-1 inhibitor, and his tumor target lesions were reduced by 29% following Neo-DCVac administration. b Computed tomography (CT) scans were performed before and after personalized Neo-DCVac immunotherapy, and representative images are shown. c Autologous PBMCs were stimulated with 15 candidate mutant peptides for 10 days, after which IFN-γ ELISpot assays were performed to assess the T-cell-specific antigen response